Pfizer Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Oct 2023 | Jul 2023 | Apr 2023 | Dec 2022 | Oct 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $41.0M | $3.12B | $-3.37B | $-2.38B | $2.33B | $5.54B | $4.99B | $8.61B |
| Depreciation & Amortization | $1.73B | $1.74B | $1.67B | $1.56B | $1.57B | $1.49B | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $1.30B | $1.30B | — | — | — | — | — | — |
| Stock-Based Compensation | $206.0M | $220.0M | $121.0M | $151.0M | $148.0M | $105.0M | $364.0M | $135.0M |
| Net Cash from Operating Activities | $-1.78B | $1.09B | $5.24B | $3.46B | $-1.21B | $1.21B | $8.58B | $5.97B |
| Investing Activities | ||||||||
| Capital Expenditures | $637.0M | $704.0M | $1.04B | $810.0M | $914.0M | $1.14B | $1.00B | $841.0M |
| Business Acquisitions | — | — | $43.41B | $0 | $25.0M | $0 | $16.77B | $0 |
| Net Cash from Investing Activities | $4.60B | $1.73B | $-11.00B | $888.0M | $-25.49B | $3.32B | $-4.41B | $-627.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Financing Activities | $-2.46B | $-4.93B | $5.44B | $-3.78B | $27.17B | $-2.77B | $-5.02B | $-5.76B |
| Net Change in Cash | $343.0M | $-2.14B | $-316.0M | $535.0M | $475.0M | $1.75B | $-869.0M | $-487.0M |
| Free Cash Flow | $-2.42B | $386.0M | $4.20B | $2.65B | $-2.12B | $73.0M | $7.58B | $5.13B |